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Abstract
In South Africa, various point-of-care hemoglobin meters are used. However, the regulatory
framework for approval, implementation and oversight of use of point-of-care hemoglobin
meters is suboptimal. We assessed the diagnostic accuracy of the HemoCue Hb 301,
STAT-Site MHgb and URIT-12 point-of-care hemoglobin meters, compared to a central labo-
ratory based reference assay, in a central laboratory and a community based clinic in Dur-
ban, South Africa. Differences in performance of the point-of-care assays, compared to the
reference assay, were more pronounced in the community based clinic. Results were rea-
sonable for the HemoCue Hb 301, but poor for the STAT-Site MHgb and the URIT-12. Poor
test performance of point-of-care hemoglobin meters, and inadequate evaluations and over-
sight in South Africa, leads to suboptimal clinical care and clinical research, and increased
costs. There is a need for proper evaluation and quality assurance of point-of-care tests, the
results of which should be made widely available to key stakeholders.
Introduction
Anemia is common in sub-Saharan Africa [1], and a frequent reason for exclusion from clinical
studies [2]. During screening procedures for enrollment in clinical studies, hemoglobin levels
are usually assessed using portable point-of-care hemoglobin meters with blood obtained by
finger prick. Portable point-of-care assays can give results within minutes, allowing rapid clini-
cal decision-making, during the encounter with the patient [3]. But point-of-care test results
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must be accurate. Inaccurate point-of-care hemoglobin meters that misdiagnose anemia may
lead to (i) false exclusion from, and inclusion in, clinical studies, and (ii) compromise clinical
care.
In South Africa there is suboptimal government regulation on the approval and use of
point-of-care assays. During screening procedures for a clinical study we observed discrepant
results between a point-of-care hemoglobin meter and a laboratory-based testing platform in a
certified central laboratory. We therefore performed a prospective study to assess the diagnos-
tic accuracy of three point-of-care hemoglobin meters in (i) a certified central laboratory and
(ii) in a community based clinic, compared to a central laboratory reference assay.
Materials and Methods
Study design
We determined the diagnostic accuracy of three point-of-care hemoglobin meters in a 2-phase
study. In phase 1, the point-of-care tests were performed in a central laboratory (Global Clini-
cal and Viral Laboratory in Amanzimtoti), compared to a laboratory reference standard. In
phase 2, the point-of-care tests were performed in a community based clinic (iThembalabantu
clinic in the Umlazi township) and the reference test was performed in the central laboratory,
using a sample obtained at the same time as the point-of-care testing. The study was approved
by the institutional review board of the University of KwaZulu-Natal. For phase 1 we used
anonymized routine blood samples. For phase 2, written informed consent was obtained from
each patient in English or isiZulu (the predominant local language).
Patient selection
Patients were eligible for inclusion in phase 2 of the study if they met the following criteria: Age
18 years or older, present for clinical care or HIV screening at one of our research clinics or
during outreach activities in the greater Durban area, willing to provide written informed con-
sent, and willing to undergo study procedure.
Specimen collection
During phase 1 of the study, we used anonymized EDTA whole blood samples submitted to
the central laboratory for routine hematology testing. During phase 2 of the study, we used
blood obtained by finger prick for the three point-of-care tests performed in the community
based clinic, and we drew EDTA whole blood samples for the reference hemoglobin test in the
central laboratory. The distance between the community based clinic and the central laboratory
was 15km. Samples were transported from the community based clinic to the central labora-
tory once or twice a day.
Hemoglobin assessments
We evaluated three point-of-care hemoglobin meters: URIT-12 (URIT Medical Electronic
Group, Guilin, Guangxi, China [4]), STAT-Site MHgb (Stanbio Laboratory, Boerne, TX, USA
[5]), and HemoCue Hb301 (HemoCue AB, Ängelholm, Sweden [6]). We compared the results
from the point-of-care hemoglobin meters to those obtained on an automated hematology ana-
lyzer (Sysmex XS-1000i, Sysmex, Kobe, Hyogo, Japan [7]) as a reference hemoglobin meter in
a South African National Accreditation System (SANAS) certified laboratory. The Sysmex XS-
1000i was used according to the manufacturer’s recommendations. Calibration was performed
annually. QC was performed daily with high, medium and low controls. The total allowable
error for hemoglobin was 4.19%. External quality assurance of the laboratory was performed
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every 4 months. All point-of-care hemoglobin meters were used according to the manufactur-
ers’ recommendations. During phase 1, one technician conducted all tests. During phase 2, one
nurse conducted all point-of-care tests in the community based clinic, and one technician sub-
sequently conducted all reference laboratory tests in the central laboratory; the technician was
blinded to the point-of-care test results. All tests were performed as single measurements. The
point-of-care tests were conducted in random order. Anemia was defined according to World
Health Organization criteria as hemoglobin< 12 g/dl for women, and< 13 g/dl for men [8].
Statistical analysis
We used GraphPad Prism and Microsoft Excel for graphical representation and statistical anal-
ysis. We assessed the accuracy, as measured by the mean difference (bias) and 95% limits of
agreement, of the HemoCue 301, URIT-12 and STAT-Site MHgb point-of-care hemoglobin
meters compared to the laboratory hemoglobin test as a reference using the Bland-Altman
method [9]. We assessed reproducibility (inter-assay variation) during phase 1 by repeat test-
ing a subset of samples with all assays.
Results and Discussion
Results phase 1, central laboratory
During phase 1 of the study, we tested samples from 60 patients in a central laboratory. We
performed phase 1 of the study from August 19 to 27, 2013. We performed all four tests on
individual samples on the same day.
As depicted in Figs 1 and 2, compared to the Sysmex XS-1000i laboratory reference, results
were most accurate for the HemoCue (bias –0.54, limits of agreement –1.28 to 0.20 g/dL, CV
<1%), less accurate for the STAT-Site MHgb (bias 1.84, limits of agreement –3.86 to 7.53 g/dL,
CV = 30.4%) and least accurate for the URIT-12 (bias 2.64, limits of agreement 0.59 to 4.69 g/
dL, CV<5%). The sensitivity and specificity of the point-of-care assays to detect or exclude
anemia in the central laboratory is summarized in S1 Table, and S1 Fig.
Results phase 2, community based clinic
During phase 2 of the study, we tested samples from 100 patients (63 women and 37 men) in a
community based clinic using three point-of-care devices with blood obtained by finger prick,
and compared them with the laboratory reference using a venous EDTA blood sample drawn
at the time of point-of-care testing. The median duration between venous blood draw and sam-
ple receipt at the central laboratory was 3 hours and 21 minutes (range 38 minutes–8 hours
and 25 minutes). The median duration between venous blood draw and test result at the central
laboratory was 5 hours and 9 minutes (range 1 hour and 15 minutes–9 hours and 37 minutes).
We performed phase 2 of the study from February 10 to 17, 2014. The median age of the 63
women and 37 men was 32 years (range 18–60) and 27 years (range 19–54), respectively. The
median Hemoglobin of the 63 women and 37 men was 11.8 g/dL (range 7.6–14.8) and 14.1 g/
dL (range 10.8–16.3), respectively.
As depicted in Figs 1 and 2, compared to the Sysmex XS-1000i laboratory reference, results
were most accurate for the HemoCue (bias 0.16, limits of agreement –2.16 to 2.47 g/dL), less
accurate for the STAT-Site MHgb (bias 0.51, limits of agreement –1.98 to 2.99 g/dL), and least
accurate for the URIT-12 (bias 2.65, limits of agreement –0.09 to 5.41 g/dL).
The sensitivity and specificity of the point-of-care assays to detect or exclude anemia in a
community based clinical setting is depicted in Table 1 and Fig 3. Of note, the sensitivity of the
URIT-12 to detect anemia in the community based clinical setting was 100%, but this number
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must be seen in context of the considerable bias in the results: out of 100 patients, 96 were diag-
nosed as anemic by the URIT-12. Of those 96 patients diagnosed by URIT-12 as anemic, only
40 (positive predictive value 42%) were truly anemic according to the laboratory reference and
the specificity was 7%, with only 4 of 60 non-anemic patients correctly diagnosed as non-ane-
mic by the URIT-12. The clinical consequence of this structural misclassification by the URIT-
12 is overdiagnosis of anemia, and overtreatment. The additional consequence in research set-
tings is that many potential study participants will needlessly be excluded from clinical studies,
based on the false assumption that they are anemic.
Discussion
We found that the diagnostic accuracy of 3 point-of-care hemoglobin meters is different in
central laboratory and community based clinic settings, with a trend towards greater variation
of results in the community based clinic, for which there are 2 possible explanations: First, in
the community based clinic setting we compared blood obtained by finger prick for the point-
of-care meter with venous blood for the reference laboratory meter. Differences between finger
stick and venous hemoglobin measurements have been observed in several studies, with finger
stick measurements both underestimating and overestimating hemoglobin levels [10, 11]. Sec-
ond, in phase 2 of the study the point-of-care test was performed by a nurse in a community
based clinic, while the central laboratory test was performed by a laboratory technician.
Fig 1. Correlation of the 3 point-of-care assays with values within the dynamic range of the reference Hemoglobin meter in 60 samples in a central
laboratory (phase 1), and 100 samples in a community based clinical setting (phase 2). In phase 1 of the study the STAT-Site had a high failure rate. It
seems that this was related to uneven migration of the sample through the sample strip, resulting in the sample migration time exceeding the maximum time
specified by the manufacturer.
doi:10.1371/journal.pone.0152184.g001
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The benefit of our 2 phase approach is that in phase 1 in a central laboratory we could
already see the structural bias of the URIT-12, and a 10% invalid results rate for the STAT-Site.
Fig 2. Bland-Altman plots comparing the reference laboratory test with the 3 point-of-care assays in phase 1 (left column) and phase 2 (right
column). In phase 1 of the study the STAT-Site had a high failure rate. It seems that this was related to uneven migration of the sample through the sample
strip, resulting in the sample migration time exceeding the maximum time specified by the manufacturer.
doi:10.1371/journal.pone.0152184.g002
Diagnostic Accuracy Point-of-Care Hemoglobin Meters
PLOS ONE | DOI:10.1371/journal.pone.0152184 April 5, 2016 5 / 11
Based on the phase 1 results we could have rejected both the STAT-Site and the URIT-12. In
phase 2 the structural bias of the URIT-12 was confirmed, but the performance of the Stat-Site
was slightly better than during phase 1. This 2 phase approach shows that good performance of
a point-of-care test in a central laboratory does not guarantee good performance in a commu-
nity based clinic setting. Evaluation of a point-of-care test in only a community based clinical
Table 1. Phase 2 (community based clinical setting) sensitivity, specificity, and predictive values for the 3 point-of-care tests to detect or exclude
anemia.
Females (12 g/dl cut-off)
Point-of-care tests reference
Outcome Positive Negative Subtotal sensitivity specificity PPV NPV
HemoCue Positive 26 8 34 72% 70% 76% 66%
Negative 10 19 29
Total 36 27 63
Stat-Site Positive 30 11 41 83% 59% 73% 73%
Negative 6 16 22
Total 36 27 63
URIT Positive 36 25 61 100% 7% 59% 100%
Negative 0 2 2
Total 36 27 63
Males (13 g/dl cut-off)
Point-of-care tests reference
Outcome Positive Negative Subtotal sensitivity specificity PPV NPV
HemoCue Positive 2 10 12 50% 70% 17% 92%
Negative 2 23 25
Total 4 33 37
Stat-Site Positive 4 10 14 100% 70% 29% 100%
Negative 0 23 23
Total 4 33 37
URIT Positive 4 31 35 100% 6% 11% 100%
Negative 0 2 2
Total 4 33 37
Females and males (using the respective cut-off values)
Point-of-care tests reference
Outcome Positive Negative Subtotal sensitivity specificity PPV NPV
HemoCue Positive 28 18 46 70% 70% 61% 78%
Negative 12 42 54
Total 40 60 100
Stat-Site Positive 34 21 55 85% 65% 62% 87%
Negative 6 39 45
Total 40 60 100
URIT Positive 40 56 96 100% 7% 42% 100%
Negative 0 4 4
Total 40 60 100
Sensitivity = % of patients with anemia, according to the reference laboratory test, that were identified as anemic by the point-of-care test; specificity = %
of patients without anemia, according to the reference laboratory test, that were identified as non-anemic by the point-of-care test; PPV, positive predictive
value = % of patients that were identified as anemic by the point-of-care test that were confirmed as anemic by the reference laboratory test; NPV,
negative predictive value = % of patients that were identified as non-anemic by the point-of-care test that were confirmed as non-anemic by the reference
laboratory test.
doi:10.1371/journal.pone.0152184.t001
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setting will make it difficult to determine causes of poor performance. Therefore we recom-
mend assessment of the diagnostic accuracy of point-of-care tests in both central laboratory
and community based (clinical) settings.
Approval and registration of diagnostics is usually based on central laboratory studies alone.
Our study confirms that independent central laboratory and community based evaluations of
diagnostic accuracy are important. Appropriate analyses of the data may reveal problems that
may not be apparent in the initial registration studies [12, 13]. Several community based evalu-
ations of point-of-care tests [14–18] have revealed problems that do not typically appear in a
controlled laboratory environment. Government regulations on the use of diagnostics in South
Africa exist but are not very detailed. There seems to be widespread use of point-of-care tests
that have not been properly evaluated. Ideally, a diagnostic test should (i) receive approval
from regulatory authorities such as the FDA, or CE-marking, and (ii) be evaluated in both cen-
tral laboratory and community based settings by at least two independent groups, according to
STARD guidelines [19–22] (http://www.equator-network.org/reporting-guidelines/stard/),
with the results published in the peer reviewed literature.
Another challenge in many African settings is that for many values the clinical laboratory
reference intervals derived fromWestern countries may not be appropriate. Karita et al
Fig 3. Correlation of the 3 point-of-care assays with values within the dynamic range of the reference hemoglobin meter in 100 samples in a
community based clinical setting in phase 2 of the study.Dots in the blue quadrant indicate that the point-of-care assay missed anemia, i.e.,
misclassified a finger prick sample as non-anemic where the venous blood sample was classified as anemic according to the reference assay in a central
laboratory. Dots in the red quadrant indicate that the point-of-care assay misclassified as anemic a sample that was non-anemic according to the reference
assay.
doi:10.1371/journal.pone.0152184.g003
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established reference intervals for routine haematology and biochemistry in healthy adults in
Eastern and Southern Africa [23]. Compared to Western reference intervals, the average hemo-
globin was lower in several populations. Many otherwise healthy adults would be defined as
anaemic, and excluded from clinical studies using inclusion and exclusion criteria based on lab-
oratory reference intervals from other populations [2].
Taken together, the combination of poor regulation, inaccurate tests, and inappropriate ref-
erence intervals creates two problems for clinical medicine, and three problems for clinical
studies in sub-Saharan Africa. The two problems for clinical medicine are that on the one hand
false anemia will lead to costly and unnecessary overtreatment, and on the other hand true ane-
mia will be missed possibly resulting in greater morbidity and associated costs. The three prob-
lems for clinical research are that (i) it is difficult to recruit per se due to inappropriate
reference intervals, (ii) inaccurate assays will decrease recruitment (false exclusion) and
increase premature termination (false inclusion), and (iii) increase the efforts, duration and
costs of clinical studies.
How can we benefit from the portability and speed of point-of-care tests, but also accurately
determine whether a patient is truly anemic? A practical solution might be an algorithm where
point-of-care results within a chosen interval around the cut-off for anemia must be followed
by a laboratory reference test. The width of the interval would depend on the accuracy of the
point-of-care assay. The patients with hemoglobin values below the interval would be classified
as anemic with a high degree of certainty with the point-of-care assay.
Diagnostic accuracy studies are relatively simple, and many laboratories in sub-Saharan
Africa perform in-house and/or community based evaluations of new assays, but few publish
the results [24, 25]. Diagnostic accuracy studies are good introductions to laboratory and clini-
cal research. Generic protocols can be developed and used, with minor modifications, for dif-
ferent tests. This is a tremendous opportunity to build research capacity, and at the same time
address the practical clinical need to assess the diagnostic accuracy of new tests.
Conclusion
In this study, we have shown that the HemoCue Hb301 is a reasonably accurate point-of-care
hemoglobin meter, but the STAT-Site MHgb and URIT-12 are not. When the assays are per-
formed in a community based setting, none of them can match the performance of a laboratory
based reference. The widespread use of an inaccurate point-of-care hemoglobin meter such as
the STAT-Site MHgb and especially the URIT-12 in the public health sector in South Africa is a
concern, as it may result in both overtreatment and undertreatment, with ensuing clinical con-
sequences and costs. There is a need for policy guidelines on the validation, approval and qual-
ity control of point-of-care assays to (i) improve patient care and (ii) ensure optimal use of
scarce resources. The proposed studies can (i) benefit clinical medicine, (ii) benefit clinical
research, and (iii) help build research capacity.
Supporting Information
S1 Fig. Correlation of the 3 point-of-care assays with values within the dynamic range of
the reference hemoglobin meter in 100 samples in a central laboratory in phase 1 of the
study, where all tests were conducted on the same sample. Dots in the blue quadrant indicate
that the point-of-care assay missed anemia, i.e., misclassified a sample as non-anemic that was
anemic according to the reference. Dots in the red quadrant indicate that the point-of-care
assay misclassified as anemic a sample that was non-anemic according to the reference.
(EPS)
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S1 Table. Phase 1 (central laboratory) sensitivity, specificity, and predictive values for the 3
point-of-care hemoglobin meters to detect or exclude anemia. Sensitivity = % of patients
with anemia, according to the reference laboratory test, that were identified as anemic by the
point-of-care test; specificity = % of patients without anemia, according to the reference labora-
tory test, that were identified as non-anemic by the point-of-care test; PPV, positive predictive
value = % of patients that were identified as anemic by the point-of-care test that were con-
firmed as anemic by the reference laboratory test; NPV, negative predictive value = % of
patients that were identified as non-anemic by the point-of-care test that were confirmed as
non-anemic by the reference laboratory test.
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